Exelixis, Inc. (0IJO.L)
USD 39.54
(1.73%)
USD 39.54
(1.73%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 196.6 Million USD | -2.42% |
| 2022 | 222.35 Million USD | -29.71% |
| 2021 | 300.29 Million USD | 160.46% |
| 2020 | 110.06 Million USD | -70.21% |
| 2019 | 369.47 Million USD | -18.28% |
| 2018 | 438.85 Million USD | 170.35% |
| 2017 | 168.29 Million USD | 848.31% |
| 2016 | -36.16 Million USD | 81.37% |
| 2015 | -119.6 Million USD | 43.55% |
| 2014 | -217.72 Million USD | -7.18% |
| 2013 | -196.36 Million USD | -87.83% |
| 2012 | -114.73 Million USD | -204.38% |
| 2011 | 100.07 Million USD | 310.82% |
| 2010 | -72.51 Million USD | 60.16% |
| 2009 | -115.57 Million USD | 28.95% |
| 2008 | -155.58 Million USD | 22.83% |
| 2007 | -157.04 Million USD | -99.91% |
| 2006 | -109.84 Million USD | -44.09% |
| 2005 | -70.86 Million USD | -25.98% |
| 2004 | -89.05 Million USD | 21.68% |
| 2003 | -77.58 Million USD | -10.43% |
| 2002 | -70.41 Million USD | -58.76% |
| 2001 | -53.43 Million USD | -412.83% |
| 2000 | -24 Million USD | 207.53% |
| 1999 | -13.1 Million USD | 14.36% |
| 1998 | -15.29 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 283.67 Million USD | 313.07% |
| 2024 Q3 | 136.07 Million USD | -31.16% |
| 2024 Q1 | 101.51 Million USD | -22.24% |
| 2023 FY | - USD | -2.42% |
| 2023 Q3 | -17.58 Million USD | -122.59% |
| 2023 Q2 | 77.85 Million USD | 170.03% |
| 2023 Q1 | 28.83 Million USD | 159.97% |
| 2023 Q4 | 88.31 Million USD | 602.27% |
| 2022 Q2 | 88.48 Million USD | 6.29% |
| 2022 Q1 | 83.24 Million USD | -28.63% |
| 2022 Q3 | 88.27 Million USD | -0.23% |
| 2022 Q4 | -48.07 Million USD | -154.46% |
| 2022 FY | - USD | -29.71% |
| 2021 FY | - USD | 160.46% |
| 2021 Q1 | -1.38 Million USD | -105.68% |
| 2021 Q2 | 126.67 Million USD | 9279.42% |
| 2021 Q4 | 116.64 Million USD | 106.72% |
| 2021 Q3 | 56.42 Million USD | -55.46% |
| 2020 Q2 | 77.73 Million USD | 41.38% |
| 2020 Q3 | -40.22 Million USD | -151.75% |
| 2020 Q4 | 24.29 Million USD | 160.4% |
| 2020 FY | - USD | -70.21% |
| 2020 Q1 | 54.98 Million USD | -28.88% |
| 2019 Q1 | 84.55 Million USD | -27.34% |
| 2019 FY | - USD | -18.28% |
| 2019 Q4 | 77.31 Million USD | -34.7% |
| 2019 Q3 | 118.4 Million USD | 25.05% |
| 2019 Q2 | 94.68 Million USD | 11.97% |
| 2018 Q1 | 118.37 Million USD | 204.15% |
| 2018 FY | - USD | 170.35% |
| 2018 Q4 | 116.37 Million USD | -10.93% |
| 2018 Q3 | 130.65 Million USD | 46.47% |
| 2018 Q2 | 89.2 Million USD | -24.64% |
| 2017 Q4 | 38.91 Million USD | -54.14% |
| 2017 Q1 | 21.56 Million USD | -45.79% |
| 2017 FY | - USD | 848.31% |
| 2017 Q3 | 84.86 Million USD | 193.08% |
| 2017 Q2 | 28.95 Million USD | 34.29% |
| 2016 Q3 | 10.37 Million USD | 144.85% |
| 2016 Q1 | -48.61 Million USD | -54.64% |
| 2016 FY | - USD | 81.37% |
| 2016 Q4 | 39.77 Million USD | 283.34% |
| 2016 Q2 | -23.13 Million USD | 52.4% |
| 2015 Q2 | -29.6 Million USD | -29.3% |
| 2015 FY | - USD | 43.55% |
| 2015 Q4 | -31.43 Million USD | 9.79% |
| 2015 Q3 | -34.84 Million USD | -17.71% |
| 2015 Q1 | -22.89 Million USD | 45.74% |
| 2014 FY | - USD | -7.18% |
| 2014 Q4 | -42.19 Million USD | 5.4% |
| 2014 Q3 | -44.59 Million USD | 26.16% |
| 2014 Q2 | -60.4 Million USD | 3.07% |
| 2014 Q1 | -62.31 Million USD | -5.88% |
| 2013 FY | - USD | -87.83% |
| 2013 Q4 | -58.85 Million USD | -5.94% |
| 2013 Q3 | -55.55 Million USD | -12.18% |
| 2013 Q2 | -49.52 Million USD | -51.41% |
| 2013 Q1 | -32.71 Million USD | -3.21% |
| 2012 Q4 | -31.69 Million USD | -38.03% |
| 2012 FY | - USD | -204.38% |
| 2012 Q1 | -21.09 Million USD | -136.83% |
| 2012 Q2 | -29.81 Million USD | -41.29% |
| 2012 Q3 | -22.96 Million USD | 22.98% |
| 2011 Q4 | 57.29 Million USD | -31.67% |
| 2011 FY | - USD | 310.82% |
| 2011 Q3 | 83.84 Million USD | 540.43% |
| 2011 Q2 | -19.03 Million USD | -55.18% |
| 2011 Q1 | -12.26 Million USD | -156.42% |
| 2010 Q2 | -13.01 Million USD | 22.28% |
| 2010 Q4 | -4.78 Million USD | -227.0% |
| 2010 Q3 | -1.46 Million USD | 88.76% |
| 2010 Q1 | -16.75 Million USD | 38.04% |
| 2010 FY | - USD | 60.16% |
| 2009 Q1 | -33.48 Million USD | 3.65% |
| 2009 Q4 | -27.03 Million USD | -64.2% |
| 2009 Q3 | -16.46 Million USD | 52.27% |
| 2009 Q2 | -34.49 Million USD | -2.99% |
| 2009 FY | - USD | 28.95% |
| 2008 Q2 | -45.38 Million USD | -4.45% |
| 2008 Q1 | -43.45 Million USD | 42.72% |
| 2008 FY | - USD | 22.83% |
| 2008 Q4 | -34.75 Million USD | 24.18% |
| 2008 Q3 | -45.84 Million USD | -1.0% |
| 2007 Q4 | -75.86 Million USD | 1.91% |
| 2007 Q2 | -35.84 Million USD | -17.42% |
| 2007 Q1 | -30.52 Million USD | -1.32% |
| 2007 FY | - USD | -99.91% |
| 2007 Q3 | -77.34 Million USD | -115.77% |
| 2006 Q1 | -26.47 Million USD | -6.27% |
| 2006 Q4 | -30.13 Million USD | -9.75% |
| 2006 Q3 | -27.45 Million USD | -6.62% |
| 2006 Q2 | -25.75 Million USD | 2.75% |
| 2006 FY | - USD | -44.09% |
| 2005 Q3 | -23.32 Million USD | -339.39% |
| 2005 Q1 | -22.68 Million USD | -471.64% |
| 2005 Q4 | -24.91 Million USD | -6.83% |
| 2005 FY | - USD | -25.98% |
| 2005 Q2 | -5.3 Million USD | 76.6% |
| 2004 Q3 | -22.5 Million USD | -10.69% |
| 2004 Q2 | -20.33 Million USD | 11.5% |
| 2004 FY | - USD | 21.68% |
| 2004 Q1 | -22.97 Million USD | -30.08% |
| 2004 Q4 | 6.1 Million USD | 127.12% |
| 2003 Q1 | -19.17 Million USD | -41.49% |
| 2003 Q2 | -20.11 Million USD | -9.03% |
| 2003 Q3 | -20.17 Million USD | 7.22% |
| 2003 FY | - USD | -10.43% |
| 2003 Q4 | -18.12 Million USD | 9.11% |
| 2002 Q1 | -15.25 Million USD | -7.5% |
| 2002 Q4 | -14.2 Million USD | 29.68% |
| 2002 FY | - USD | -58.76% |
| 2002 Q3 | -19.31 Million USD | 5.36% |
| 2002 Q2 | -20.29 Million USD | -29.66% |
| 2001 Q3 | -11.47 Million USD | -114.3% |
| 2001 Q2 | -12.02 Million USD | 44.9% |
| 2001 Q1 | -9.72 Million USD | -19.19% |
| 2001 Q4 | -17.32 Million USD | -27.53% |
| 2001 FY | - USD | -412.83% |
| 2000 Q4 | -8.15 Million USD | -31.36% |
| 2000 Q1 | -3.23 Million USD | 0.0% |
| 2000 Q2 | -6.41 Million USD | -98.45% |
| 2000 FY | - USD | 207.53% |
| 2000 Q3 | -6.2 Million USD | 3.14% |
| 1999 FY | - USD | 14.36% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 220.528% |
| Dynavax Technologies Corporation | 9.66 Million USD | -1933.954% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 267.108% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 101.743% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -100.079% |
| Perrigo Company plc | 646.2 Million USD | 69.576% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 173.911% |
| Illumina, Inc. | -608 Million USD | 132.336% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 98.18% |
| Nektar Therapeutics | -243.1 Million USD | 180.871% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 143.785% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 93.962% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 289.419% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 627.323% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 36.638% |
| Waters Corporation | 1.02 Billion USD | 80.768% |
| Biogen Inc. | 2.37 Billion USD | 91.729% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 324.876% |
| Adicet Bio, Inc. | -136.53 Million USD | 243.994% |
| Evolus, Inc. | -41.81 Million USD | 570.227% |
| bluebird bio, Inc. | -167.16 Million USD | 217.612% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 323.449% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 230.974% |
| FibroGen, Inc. | -261.4 Million USD | 175.21% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 88.277% |
| Homology Medicines, Inc. | -47.75 Million USD | 511.68% |
| Geron Corporation | -174.78 Million USD | 212.484% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 186.183% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 542.432% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 313.514% |
| Myriad Genetics, Inc. | -67.8 Million USD | 389.973% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 95.776% |
| OPKO Health, Inc. | -65.51 Million USD | 400.082% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 294.989% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 138.83% |
| Zoetis Inc. | 3.68 Billion USD | 94.665% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 488.757% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 83.11% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 95.731% |
| uniQure N.V. | -253.1 Million USD | 177.678% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 644.876% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 452.611% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 187.382% |
| Verastem, Inc. | -83.16 Million USD | 336.397% |
| Imunon, Inc. | -20.78 Million USD | 1046.008% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 185.475% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 144.764% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 52.751% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -81.494% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 56.499% |
| TG Therapeutics, Inc. | 26.1 Million USD | -653.264% |
| Blueprint Medicines Corporation | -474.61 Million USD | 141.424% |
| Insmed Incorporated | -654.73 Million USD | 130.028% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 156.909% |
| Incyte Corporation | 919.42 Million USD | 78.617% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 138.908% |